GNExT: An Analysis Tool Connecting GWAS Variants to Disease Networks and Therapeutic Targets
Background
Genome-Wide Association Studies (GWAS) have played a central role in identifying genetic variants associated with diseases. However, existing analyses typically focus on confirming the statistical significance of individual Single Nucleotide Polymorphism (SNP) variants. Most of the identified variants are located in non-coding regions and do not encode proteins, making it difficult to understand how they disrupt cellular pathways and cause disease.
Network Medicine, which studies intracellular molecular interactions, has emerged as a way to bridge this gap. Connecting variant information with disease mechanisms requires combining large-scale genomic data with protein interaction networks. However, due to complex data processing and computational procedures, there has been a lack of user-friendly analysis platforms for researchers.
Key Findings
A joint research team, including the Technical University of Munich (TUM), developed a web-based platform called GNExT (GWAS Network Exploration Tool) that connects genomic data with network medicine, and published their findings in the international journal Nature Genetics. This platform automates the entire process of merging genetic variant signals at the gene level and linking them to protein interaction networks.
The core Nextflow pipeline standardizes input GWAS summary statistics, and then uses the Ensembl Variant Effect Predictor (VEP) and Multi-marker Analysis of Genomic Annotation (MAGMA) tools to diagnose the biological effects of genetic variants and merge the signals.
The processed signals are linked to Drugst.One, a drug repurposing analysis tool, to explore potential drug targets within the protein interaction network. The researchers validated the system by inputting thousands of trait data from the Pan-UK Biobank and olfactory perception genomic data. The analysis showed that a large amount of genetic information was quickly converted into disease networks, and a network of previously unknown genes and candidate drugs was visualized.
The design also maximizes user convenience. The backend uses Python Django (Django REST API), and the frontend uses the Vue.js framework to achieve fast response times. It incorporates the Typesense engine to support real-time search, and the entire system is packaged in Docker for easy installation.
Significance and Prospects
The development of GNExT is expected to shorten the cycle from genetic analysis results to actual drug development. There are reports that using genomic information can double the clinical success rate of new drug development, which means that academic and bio-venture companies will have an environment to discover therapeutic targets without expensive computing infrastructure.
However, the accuracy of the platform's predictions depends entirely on the reliability of existing protein interaction databases. The currently accumulated gene maps have limitations in perfectly reflecting the subtle characteristics of specific tissues or cell types. In order to accurately select valid targets, follow-up work is needed to further link single-cell-level molecular interaction networks or tissue-specific transcriptomes.
Nature Genetics, Published online: 17 August 2026; doi:10.1038/s41588-026-02708-6Bridging the gap between GWAS and network medicine with GNExT
In clinical settings and the biopharmaceutical industry, GNExT is a key tool for accelerating personalized medicine and efficient new drug development. For example, when a pharmaceutical company develops a treatment for a specific autoimmune disease, inputting the genomic data of tens of thousands of patients into GNExT can quickly identify the key nodes of the protein interaction network that causes the disease. It is also possible to screen for candidate substances that inhibit the protein network among existing drugs and derive drug repurposing scenarios.
It is also expected to be useful in the design of clinical trials. By pre-selecting a patient population with genetic interaction networks that are likely to respond to a specific drug, the cost of clinical trials can be reduced and the success rate can be maximized. In the case of rare diseases with few patients and unclear pathogenesis, it is also possible to identify potential therapeutic target proteins from a small amount of genetic information and provide clues for drug development.